A Platform Designed for Translational Research
OncoFirm is developing its technology around a staged translational pathway:
Biomarker Discovery & Selection → Assay Engineering → Prototype Development → Analytical Validation → Digital Integration → Clinical Feasibility → Regulatory Development → Manufacturing Scale-Up → Commercialization
This development model allows specific scientific and engineering questions to be addressed through clearly defined research objectives and measurable milestones.
It also creates opportunities for collaboration across multiple disciplines, including:
Cancer Biology • Clinical Oncology • Biostatistics • Immunochemistry • Assay Development • Biomedical Engineering • Artificial Intelligence • Regulatory Science • Clinical Research • Manufacturing
Why OncoFirm™
Connecting Diagnostics, Digital Technology and Translational Oncology
The potential value of the OncoFirm platform extends beyond a conventional lateral flow test.
Our development strategy integrates the biological assay, electronic reader, computational interpretation, calibration information, quality-control data, and manufacturing metadata into a connected diagnostic architecture.
This approach is intended to support:
- Rapid point-of-care testing
- Objective digital measurement
- Quantitative biomarker assessment
- Multiplex assay development
- Standardized result interpretation
- Test-level quality verification
- Longitudinal diagnostic information
- Scalable product development
- Integration with modern healthcare information systems
The result is a technology platform being developed with both scientific translation and commercial scalability in mind.
Collaboration Areas
OncoFirm welcomes qualified organizations and professionals interested in participating in:
- Sponsored research
- Grant-supported collaborations
- SBIR/STTR research partnerships
- Translational research
- Biomarker studies
- Assay-development programs
- Clinical feasibility studies
- Biostatistical planning
- Scientific advisory roles
- Regulatory strategy
- Technology licensing
- Co-development
- Manufacturing partnerships
- Strategic investment
- Commercialization partnerships
Advancing the Next Generation of Early Cancer Diagnostics
Innovative Point-of-Care Cancer Biomarker Technology Designed for Translation, Validation & Commercialization
OncoFirm™ Diagnostics is a biotechnology company developing next-generation cancer diagnostic technologies designed to make biomarker detection faster, more accessible, and easier to deploy at the point of care.
Our development platform combines proprietary fluorescent lateral flow immunoassays, cancer-associated biomarker detection, digital fluorescence reading, AI-assisted signal interpretation, and scalable diagnostic workflows within an integrated technology ecosystem.
Our mission is straightforward:
Advance technologies that can help bring earlier cancer detection closer to the patient.
OncoFirm welcomes opportunities to work with federal research programs, private foundations, academic investigators, cancer research centers, clinical collaborators, strategic investors, and industry partners interested in accelerating innovative diagnostic technologies from research through validation and commercialization.
[Explore Our Technology]
[Research & Funding Opportunities]
[Collaborate With OncoFirm]
Our Technology Platform
Fluorescent Lateral Flow Diagnostics for Cancer Biomarker Detection
At the center of the OncoFirm™ platform is a proprietary fluorescent lateral flow immunoassay architecture being engineered for the detection and quantitative assessment of selected cancer-associated biomarkers.
The platform integrates several complementary technologies:
- Cancer-associated antigen and biomarker detection
- High-sensitivity fluorescent reporter systems
- Lateral flow immunoassay engineering
- Multiplex biomarker testing capabilities
- Portable electronic fluorescence detection
- Digital signal processing
- AI-assisted interpretation and confidence assessment
- Internal calibration and quality-control mechanisms
- Test and manufacturing metadata integration
- Cloud-enabled diagnostic data architecture
- Scalable manufacturing concepts
Rather than developing only an individual test, OncoFirm is building a platform technology capable of supporting multiple cancer biomarker applications and future multiplex diagnostic configurations.
[Learn About Our Fluorescent Lateral Flow Platform]
The Challenge: Earlier Detection Requires Better Access to Diagnostic Information
Cancer outcomes are strongly influenced by the stage at which disease is identified.
Yet many diagnostic workflows continue to depend on centralized laboratories, sophisticated instrumentation, specialized personnel, and multi-step testing processes.
These requirements can create barriers to rapid diagnostic assessment, particularly in environments where laboratory infrastructure or immediate access to advanced testing is limited.
OncoFirm is developing technology intended to address this challenge through a portable, digitally interpreted cancer biomarker testing platform designed around rapid lateral flow diagnostics.
Our long-term objective is to help create diagnostic workflows capable of providing clinicians with meaningful biomarker information closer to the point of care.
